Galectin Therapeutics Inc. (GALT) Risk Assessment & Volatility Analysis

Comprehensive risk assessment and volatility analysis for GALT including beta analysis, market risk, financial risk, and investment risk evaluation. Understand the potential risks and rewards of investing in GALT stock with expert risk management insights.

Risk Assessment Summary

High short interest

High price volatility

Governance Risk

Overall Risk Score

N/A

Audit Risk

N/A

Board Risk

N/A

Compensation Risk

N/A

Shareholder Rights Risk

N/A

Market Risk

Beta (5Y Monthly)

0.96Moderate

52-Week Change

204.62%Very High

S&P 500 52-Week Change

12.43%Very High

Short Interest Ratio

17.71Very High

Short % of Float

14.84%Very High

Volatility (Annualized)

125.24%Very High

Financial Risk

Total Debt

$126.05M

Enterprise Value

$499.71M

Profit Margins

0.00%Very High

Earnings Growth (QoQ)

N/A

Net Income to Common

$-37442000.00

Book Value

$-1.95

Risk vs Reward Analysis

Risk Factors

Beta: 0.96

Volatility: 125.24%

Short Interest: 17.71

Potential Rewards

52-Week Change: 204.62%

Earnings Growth: N/A

Profit Margin: 0.00%